Aegerion Pharma Takes Third Shot at IPO

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug developer focused on cardiovascular and metabolic diseases, has re-filed for an $86.25 million IPO. This the the company’s third IPO filing, having twice before filed and withdrawn due to “market conditions.”

Leerink Swan and Lazard Capital Markets are serving as co-lead underwriters.

Aegerion has raised over $44 million in total VC funding, from firms like Index Ventures, Advent International, Alta Partners, Scheer & Co. and MVM Life Science Partners.

Leave a Reply

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget